Product Details
Product Name:
LY88074 |
CAS No.:
177744-96-6 |
Purity:
98.05% |
Supply Ability:
10g |
Release date:
2024/11/12 |
Product Introduction
Bioactivity
名稱 | LY88074 |
描述 | LY88074 is a raloxifene analog in which the basic side chain has been removed. LY88074 is an agonist of ERβ (EC50 = 232 nM).This compound stimulates uterine cell proliferation. |
體外活性 | The interaction of LY88074 with collagen matrix, although significant, is less than the interaction found with Raloxifene.Removal of the aminoethylpiperdine moiety, as in LY88074, reduces bone binding, compared to Raloxifene[3].? |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 3.62 mg/mL (10 mM), Sonication is recommended.
|
關(guān)鍵字 | LY88074 | LY-88074 | LY 88074 |
相關(guān)產(chǎn)品 | Kaempferol | Tamoxifen | Mifepristone | Estradiol | Astragaloside IV | Estradiol benzoate | Progesterone | Melatonin | Allura Red AC | Natamycin | Ethisterone | Estrone |
相關(guān)庫(kù) | 核受體化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:183060-99-3
$1980.00 / 50mg
-
CAS:63675-88-7
$1980.00 / 50mg
-
CAS:63675-87-6
$1980.00 / 50mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$197.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-12 |